A carregar...
OR18-01 Effect of Teprotumumab on Proptosis Reduction Across Various Demographic Sub-Groups
Introduction: Teprotumumab, an insulin-like growth factor 1 receptor inhibitory monoclonal antibody, was recently shown to significantly reduce proptosis in patients with active, moderate-to-severe thyroid eye disease (TED) in phase 2 and phase 3 clinical trials.(1,2) Prior analyses have demonstrate...
Na minha lista:
| Publicado no: | J Endocr Soc |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7208043/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.1103 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|